Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises on the sale of GleSYS
Mandate

Vinge advises on the sale of GleSYS

March 21, 2023 M&A

Vinge has advised the principal owners VIA equity and CEO Glenn Johansson as well as other minor shareholders in connection with the sale of GleSYS to the Luxembourg-based infrastructure fund Cube Infrastructure Managers.

GleSYS owns data centres in Falkenberg, Stockholm and Oulu (Finland) and co-operates with market leaders in Europe. GleSYS' data centres use 100 per cent renewable energy and the waste heat is recycled to heat residential properties.

Vinge's team primarily consisted of Johan Winnerblad, Per Kling, Nando Basic, Olivia Belding, Emelie Schoning and Christoffer Widström.

Read more here

 

 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026